The first two authors equally contributed to the work
Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions
Article first published online: 27 NOV 2009
© 2009 John Wiley & Sons A/S
Volume 65, Issue 5, pages 657–661, May 2010
How to Cite
Vultaggio, A., Matucci, A., Nencini, F., Pratesi, S., Parronchi, P., Rossi, O., Romagnani, S. and Maggi, E. (2010), Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy, 65: 657–661. doi: 10.1111/j.1398-9995.2009.02280.x
Edited by: Marek Kowalski
- Issue published online: 1 APR 2010
- Article first published online: 27 NOV 2009
- Accepted for publication 22 October 2009
- anti-infliximab antibodies;
- drug allergy;
- drug-specific IgE and IgM
To cite this article: Vultaggio A, Matucci A, Nencini F, Pratesi S, Parronchi P, Rossi O, Romagnani S, Maggi E. Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy 2010; 65: 657–661.
Background: Infliximab is a chimeric monoclonal antibody against TNF-α useful in the treatment of many chronic inflammatory diseases. Severe anaphylaxis has been reported during therapy, although the exact mechanism has not been fully defined. The reactions have been related to the infliximab immunogenicity and development of specific antibodies.
Aims of the study: Evaluation of the development of IgE and non-IgE antibodies to infliximab and their relationship with infusion reaction.
Methods: Seventy-one patients (11 reactives, 11 therapeutically nonresponders, and 49 unreactive therapeutically responders) and 20 non–infliximab-exposed control subjects (ten rheumatoid arthritis, five spondyloarthropathies, five vasculitis) were evaluated for the presence of IgE (ImmunoCAP assay), IgM, and non–isotype-specific (ELISA assays) anti-infliximab antibodies. Sera were obtained at baseline and during the course of treatment, before each infliximab infusion.
Results: Eleven out of 71 patients had a hypersensitivity reaction to infliximab. Non–isotype-specific anti-infliximab antibodies were detected in eight reactive and two nonresponder patients. Three patients with severe reactions displayed anti-infliximab IgE antibodies and positive skin testing. Detectable levels of anti-infliximab IgM antibodies were shown in three additional IgE- and skin testing-negative patients. IgE and IgM antibodies to infliximab were not detectable in the two nonresponder patients. Antibodies developed before the 2nd and the 3rd infusion, and their appearance was strictly related to the timing of the reaction.
Conclusions: This report indicates that in some patients with infliximab-related severe reactions, IgE or IgM antibodies against infliximab were detectable. The majority of reactions could be predicted by the appearance of anti-infliximab antibodies.
Infliximab is a chimeric monoclonal antibody against TNF-α useful in the treatment of immuno-mediated inflammatory diseases. Anaphylaxis has been reported during this therapy, although the exact pathogenic mechanism has not been fully defined. The reactions have been related to the infliximab immunogenicity and development of specific antibodies (Abs) (1, 2). It has been shown that antibodies to infliximab (ATI) are mainly of the IgG isotype; however, the existence of other classes of Abs has been postulated (3) but never shown.
Seventy-one consecutive infliximab-treated patients suffering from rheumatoid arthritis (n = 23), spondyloarthropathies (n = 14), and systemic vasculitis (n = 34) were evaluated. At enrolling, patients had never been administered with biological agents. According to the recommendations, infliximab was always associated with methotrexate in patients suffering from rheumatoid arthritis. All enrolled patients were treated with infliximab as resistant to traditional immunosuppressive therapies, including methotrexate, cyclosporine, and cyclophosphamide.
We defined reactive patients those with acute infusion reactions occurring during or within 24 h after infusion. Systemic reactions were classified as mild, moderate, or severe according to the grading system for generalized hypersensitivity reaction proposed by Brown et al. (4). Eleven patients were defined as therapeutically nonresponders because increased doses and/or shortened intervals between infusions were needed. Twenty non–infliximab-exposed subjects suffering from rheumatoid arthritis (n = 10), spondyloarthropathies (n = 5), and vasculitis (n = 5) were enrolled as control group. Written informed consent was provided by all patients under an institutional review board-approved protocol. Patients were infused with infliximab over a 2-h period at 0, 2, 6 weeks and every 8 weeks thereafter. Pretreatment with hydroxyzine (25 mg) and prednisone (25 mg) was routinely performed. Serum samples were taken before each infusion.
Detection of anti-infliximab antibodies
Non–isotype-specific ATI were measured by a double-capture ELISA kit (Immundiagnostick AG) according to the manufacturer’s instructions. Anti-infliximab IgM Abs were measured by a modified ELISA. Samples (100 μl of serum diluted 1 : 200) were incubated overnight (4°C) into 96-well microtiter plates precoated with infliximab (Immundiagnostick AG). After washing, biotinylated anti-human IgM (0.5 μg/ml) (mouse IgG1k; Pharmingen, San Diego, CA, USA) was added for 1 h at RT. After 1 h of incubation with avidine peroxidase and subsequent addition of the substrate solution (TMB) for 15′, the reaction was stopped with 0.4M sulfuric acid. In both assay, sera were considered to be positive when exceeded the cut off value [twice the optical density (OD) of the negative control].
Total and anti-infliximab IgE antibodies serum detection
IgE ATI were measured with the use of the streptavidin ImmunoCAP assay (kindly provided by Phadia Diagnostics, Uppsala, Sweden) as previously reported (5, 6). The threshold value for a positive result was 0.10 kUA/l. Total serum IgE detection was performed by CAP system immunoassay (Phadia Diagnostics).
Skin testing was carried out with the commercial infliximab preparation; the starting concentrations were 1 : 1000 for the prick test and 1 : 10 000 for the intradermal test. In both prick and intradermal testing, a minimum wheal area of 3 mm in diameter or an increase of area >3 mm was considered as a positive response compared to a negative response to the saline control. Undiluted infliximab preparation did not show any irritating effect in non–infliximab-exposed control subjects.
A χ2-test was used to analyze patients groups and P < 0.05 value considered as significant.
Fifteen acute reactions out of 1041 infusions (1.44%) were observed in 11 out of 71 patients (15.4%). Two reactions (13.4%) were classified as mild (characterized by urticaria), 8 (53.3%) as moderate (characterized by urticaria, chest tightness and dyspnea, vomiting), and 5 (33.3%) as severe because characterized by oxygen desaturation (<92%), hypotension (systolic blood pressure < 90 mmHg), and confusion (Table 1). All patients experienced one reaction, with the exception of patient number 6 who displayed recurrent (totally 5) reactions. All these five reactions were not severe, so the patient was retreated by increasing the dose of steroids during pretreatment and reducing the rate of infusion. Despite these procedures, reactions still occurred and infliximab therapy was stopped after the fifth reaction.
|Patients (n)||Gender/age||Disease (n)||Grading of reaction*||Atopy/total IgE (kU/l)||SPT||Intradermal|
|Unreactive (49)||F/M (29/20) 48 ± 9†||RA (15)||–||Yes/no (11/38) 46.5 ± 8.1†||0/32‡||0/32‡||0/32‡|
|Nonresponders (11)||F/M (3/8) 47 ± 5†||RA (3)||–||Yes/no (2/9) 30.2 ± 7.6†||0/11||0/11||0/11|
|Controls (20)||F/M (12/8) 51 ± 18†||RA (10)||–||Yes/no (6/14) 65.9 ± 15.2†||0/20||0/20||0/20|
By using a non–isotype-specific double format ELISA test, we evaluated the presence of ATI in all treated patients (11 nonresponders, 11 reactive-, and 49 unreactive responders) and in 20 non–infliximab-exposed control subjects. Serum ATI were detected in a significantly (P < 0.03) higher proportion of reactive patients (8 out of 11, 72.7%) compared to nonresponders (2 out of 11, 18.1%). The ATI titer (expressed as mean OD ± SEM) was significantly higher in reactive patients than in nonresponder patients (0.76 ± 0.27 vs 0.08 ± 0.02; P < 0.002). All unreactive patients resulted ATI negative as well as non–infliximab-exposed control subjects (Fig. 1A). Unreactive patients resulted ATI negative even after many treatments (data not shown). ATI were detectable in the sera of reactive patients with severe (n = 4) and moderate (n = 4) reactions.
We investigated the hypothesis that IgE Abs against infliximab were involved in adverse reactions using an infliximab-bound CAP system. IgE ATI were detectable in 3 out of 11 (27.2%) reactive patients (Fig.1B). To confirm the specificity of the assay, we showed that the addition of increasing doses of infliximab resulted in a significant (more than 70% with the dose of 1 μg/ml) dose–dependent reduction of specific IgE (data not shown). Because infliximab is a chimeric molecule, mouse IgG was used as control and a similar inhibition was observed. The three patients showing detectable serum ATI IgE developed a positive intradermal test at immediate lecture performed with 1/10 diluted drug. All tested unreactive responder and controls subjects displayed negative skin testing (Table 1).
Because ATI IgE were detectable in the sera of only three out of eight ATI-positive reactive patients, the presence of IgM anti-infliximab Abs was investigated. By using a modified ELISA test, significantly higher levels of ATI IgM were found in reactive patients (0.86 ± 0.24) compared to unreactive subjects (0.18 ± 0.03) and controls (0.25 ± 0.06; P < 0.02 and P < 0.05, respectively). In particular, high levels of IgM ATI were found in three IgE ATI-negative patients (Fig. 1C and Table 2).
|Patients||Grading of reaction||ATI appearance*||Infusion inducing reaction||Non–isotype-specific ATI||ATI isotype|
|6||Moderate||ND||3rd, 4th, 5th, 7th, 9th||+‡||+||Neg|
IgE and IgM ATI were not detectable in the two nonresponder ATI-positive patients.
Finally, we asked whether a time relationship between the ATI appearance and the infliximab reaction could be shown. The detection of ATI in serum collected before the first infliximab infusion resulted negative in all subjects. Antibodies were detected in the sera collected before the 2nd and the 3rd infusion, and their appearance was strictly related to the timing of the reaction (Table 2). Monitoring the ATI titer, a progressive but quite fast decrease of ATI (IgE included), starting from 7 days after the reaction was observed (Fig. 1D). Of note, two out of the three patients developed reactions during the second infusion in the second course of treatment, after a period of therapy interruption.
We analyzed the humoral immune response to infliximab, by using a combination of different assays, able to detect non–isotype-specific, IgE, and IgM anti-infliximab Abs. We totally observed ATI development in 10 out of 71 infliximab-treated patients, the majority of them (n = 8) being patients showing infusion reactions, whereas two positive sera were found in the group of nonresponder subjects. Our results show that a proportion of infliximab-related reactions were associated with the appearance of IgE ATI. To our knowledge, this is the first report showing serum IgE ATI and their strict relationship to acute severe reactions. The specificity of these Abs has been directed toward the murine part of the chimeric biological agent as demonstrated by the inhibition assays performed both with the drug and the mouse Ig. The low titer of IgE ATI observed, may be because of the intrinsic characteristics of the infliximab and/or to the time-limited exposure of our patients. Different than the results obtained by Chung on cetuximab (5), we excluded pre-existing sensitization in our patients. The progressive decrease of ATI IgE after the discontinuation of therapy is in agreement with this. Because a hypersensitivity reaction was suspected, skin tests (prick and i.d.) with the biological agent were performed. In our experience, the pathogenetic role of IgE ATI is supported by the positive results of infliximab skin testing. Of note, skin tests for monoclonal antibodies have been performed in few case series of patients with infusion-related reaction (3, 7), and they obviously need to be performed on much more cases for standardization.
Some data suggest that immunological mechanisms other than type I hypersensitivity may be involved in protein-induced fatal anaphylaxis, at least in animal models (8, 9). We demonstrate that the presence of IgM ATI is involved in severe reaction. In two ATI-positive but IgE- and IgM-negative patients, a role for anti-drug IgG isotype may be envisaged. Of note, two out of three patients with adverse reactions and no detectable ATI of all isotypes did not show severe symptoms. At present, the exact mechanisms involved in these patients remain unclear.
Finally, this study defines a timing relationship between the ATI appearance and the infliximab reaction. It is interesting to note that in three patients, ATI were detectable at the second course of treatment after the first infusion suggesting a sort of sensitization phase (first course of treatment) and a challenge phase (second course of treatment). This agrees with previous studies describing an effect of therapy discontinuation on the prevalence of infliximab reaction (10).
This report clearly indicates that the majority of reactions could be predicted by the appearance of anti-infliximab Abs. By monitoring these Abs, at least for the first five infusions, it is possible to identify potentially reactive patients and, thus, improve the infliximab safety profile. The availability of an assay able to detect ATI IgE Abs appears to have significant relevance from a clinical point of view, taking into account the increasing utilization of biological drugs.